XML 29 R18.htm IDEA: XBRL DOCUMENT v3.23.2
Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2023
USD ($)
shares
Jun. 30, 2022
USD ($)
Jun. 30, 2023
USD ($)
shares
Jun. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
Number of Operating Segments     1    
Revenue from Contract with Customer, Excluding Assessed Tax $ 837,159 $ 658,553 $ 1,815,211 $ 1,306,980  
Accounts Receivable, Allowance for Credit Loss, Ending Balance 0   0   $ 0
Deferred Tax Assets, Net $ 17,100,000   $ 17,100,000   $ 15,500,000
Deferred Tax Assets, Valuation Allowance Coverage, Percent     100.00%   100.00%
Other Income     $ 1,018,000 $ 250,000  
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares     5,031,097    
Share-Based Payment Arrangement [Member]          
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares 5,619,491   5,619,491    
Restricted Stock Units (RSUs) [Member]          
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares 163,044   163,044    
Share-Based Payment Arrangement, Option [Member]          
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares 5,456,447   5,456,447    
Customer Concentration Risk [Member] | Revenue Benchmark [Member]          
Concentration Risk, Number of Customers 8 7 8 11  
Concentration Risk, Significant Customers 3 4   3  
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Non-US [Member]          
Concentration Risk, Number of Customers 2 4 2 5  
Revenue from Contract with Customer, Excluding Assessed Tax $ 98,000 $ 239,000 $ 187,000 $ 375,000  
Concentration Risk, Percentage 12.40% 38.90% 10.80% 32.70%  
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Three Significant Customers [Member]          
Revenue from Contract with Customer, Excluding Assessed Tax $ 525,000   $ 1,152,000 $ 592,000  
Concentration Risk, Percentage 66.20%   66.70% 51.60%  
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Four Significant Customers [Member]          
Revenue from Contract with Customer, Excluding Assessed Tax   $ 513,000      
Concentration Risk, Percentage   83.50%      
Customer Concentration Risk [Member] | Accounts Receivable [Member]          
Concentration Risk, Number of Customers     8   6
Concentration Risk, Significant Customers     3   2
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Non-US [Member]          
Concentration Risk, Number of Customers     3   4
Concentration Risk, Percentage     8.10%   27.40%
Accounts Receivable, after Allowance for Credit Loss $ 60,000   $ 60,000   $ 91,000
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Three Customers [Member]          
Concentration Risk, Percentage     81.20%    
Accounts Receivable, after Allowance for Credit Loss $ 623,000   $ 623,000    
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Two Customers [Member]          
Concentration Risk, Percentage         88.20%
Accounts Receivable, after Allowance for Credit Loss         $ 291,000
Supplier Concentration Risk [Member] | Contract Research Organizations [Member]          
Concentration Risk, Number of Suppliers 3 2 3 2  
Supplier Concentration Risk [Member] | Contract Research Organizations [Member] | Three CROs [Member]          
Concentration Risk, Percentage 99.40%   97.60%    
Research Services Purchased $ 1,586,000   $ 2,662,000    
Supplier Concentration Risk [Member] | Contract Research Organizations [Member] | Two CROs [Member]          
Concentration Risk, Percentage   96.20%   96.50%  
Research Services Purchased   $ 1,299,000   $ 2,794,000  
Supplier Concentration Risk [Member] | Accounts Payable [Member]          
Concentration Risk, Number of Suppliers     3   3
Supplier Concentration Risk [Member] | Accounts Payable [Member] | Three CROs [Member]          
Concentration Risk, Percentage     86.50%   79.70%
Accounts Payable $ 816,000   $ 816,000   $ 1,018,000
Alphazyme [Member]          
Proceeds from Sale, Maturity and Collection of Investments     $ 1,300,000